Several and most recent studies have shown that idiopathic pulmonary fibrosis (IPF) has a high mortality rate and the therapy used is almost noneffective. Any serum biomarker that predicts better clinical outcomes would be useful to disease stages, prognosis, and need for other and more aggressive therapy, and may be beneficial to the patients in clinical trials. This study aimed to measure the level of surfactant protein-D (SP-D) in the serum of patients with IPF, its relation with clinical manifestations, and its role in predicting the outcome of the patients (prognosis, progression, or regression of the disease, and quality of life) on the basis of assessment of quality of life using the Arabic version of St. George's respiratory questionnaire.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a variant of chronic, fibrosing interstitial pneumonia, present in older adults, characterized by histopathologic and/or radiologic features of usual interstitial pneumonia (UIP) [1] . Surfactant protein-D (SP-D) is produced by alveolar epithelial type II cells and is essential for lung innate immunity. Serum level of SP-D is elevated in IPF and other lung diseases mainly because of hyperplasia of type II pneumocyte [2] . In IPF acute exacerbation, serum SP-D is highly elevated, making the diagnosis much easier [3] . SP-D is the second hydrophilic C-type lectin SP that is also a collectin [4] . The SP-D collagen-like domain is larger than the SP-A domain and is related directly to the cysteine rich domain domain [5] . SP-D is produced by both type II and Clara cells. SP-D higher percentage is dissolved in a watery residue capable of binding to phosphatidylinositol, whereas SP-A, SP-B, and SP-C are mostly related to lipids; its role in surfactant homeostasis regulation is less known, whereas surfactant metabolism disturbances were observed in mice [6] .
Recently, serum SP-A and SP-D levels were observed to be elevated in idiopathic UIP or nonspecific interstitial pneumonia patients compared with healthy controls [7] .
Participants and methods
This study was carried out on 50 participants selected from among inpatients and outpatients of the Chest Department, Tanta University Hospital, from June 2013 to June 2014. The ethics committee for research approved the study and informed consent was obtained from all participants.
Participants were classified into two groups:
(1) Group I included 15 apparently healthy non smoker volunteers as a control group (seven men and eight women); their ages ranged between 23and 58 years. (2) Group II included 35 patients diagnosed with IPF (19 men and 16 women); their ages ranged between 35 and 77 years. Twenty (57.14%) out of 35 patients were nonsmokers, 11 (31.43%) patients were smokers, and four (11.43%) patients were ex-smokers.
Inclusion criteria of the IPF group: patients were selected according to the American Thoracic Society and the European Respiratory Society [8] . In 2011, an official joint statement was issued providing guidance for the diagnosis and management of IPF. These guidelines include a revision of the diagnostic criteria as follows:
(1) Exclusion of other known causes of interstitial lung disease (e.g. domestic and occupational environmental exposures, connective tissue disease, and drug toxicity). The previous guidelines using major and minor criteria for the clinical (i.e. nonpathological) diagnosis of IPF were discarded as it is now clear that, in an appropriate clinical setting, the presence of a classical UIP pattern on the HRCT scan is sufficient for a diagnosis of IPF to be made [8] .
Thus, in the present study, clinical, and radiological (HRCT) criteria were used to confirm the diagnosis of IPF.
Exclusion criteria
Patients with a history of environmental or occupational exposure, hypersensitivity pneumonitis, collagen vascular disease, patients who had acute lung injury, patients who had a history of other chronic respiratory diseases (bronchial asthma, chronic obstructive pulmonary disease, and lung cancer), chronic heart, renal, or liver failure, and patients who were under oral corticosteroids or cytotoxic drugs therapy were excluded.
The following assessments were performed for all participants:
(1) Thorough assessment of history, with a focus on age and age of onset. After obtaining written consent from all participants, two samples of blood were taken: one was venous and the other was arterial; 3 ml of blood was withdrawn from every participant (Tables 1-4 
and Figs. 1-4).
Determination of human surfactant protein-D (ng/ml) Serum SP-D was detected using the natural human surfactant protein-D ELISA kit (USA).
Statistical analysis was carried out using SPSS v.20 (SPSS Inc., Chicago, Illinois, USA) using mean, SD, and χ 2 -test.
Results
The HRCT score showed statistically significant positive correlations with serum levels of SP-D (r=0.578, P<0.001) ( Figs. 5-7 ).
Discussion
The aim of this study was to measure SP-D serum levels in IPF and its relation to clinical manifestations, and also its role in predicting patient outcome (prognosis, progression or regression of the disease, 
Figure 1
Spirometric data in both groups. FEV, forced expiratory volume in 1 s; FVC, forced vital capacity. Arterial blood gases in groups I and II.
and quality of life) on the basis of assessment of quality of life using the Arabic version of SGRQ [9] . In the present study, the mean value of SGRQ total score was found to be statistically significantly higher in the IPF group compared with the controls.
The study found the mean SP-D value to be statistically significantly higher in the IPF group compared with the control group.
Baumgartner et al. [10] studied about 248 cases and 491 control participants identified through random- ANOVA, analysis of variance; SP-D, surfactant protein-D; *P<0.05, significant.
Figure 4
Surfactant protein-D level in terms of smoking habits in group II. digit dialing matched in terms of sex, age, and geographic region. More cases (72%) than control participants (63%) had a history of smoking. The odds ratio (OR) for smoking was 1.6 (95%CI: 1.1-2.4). The risk was significantly elevated for former smokers (OR=1.9; 95%CI: 1.3-2.9) and for smokers with 21-40 pack-year (OR=2.3; 95%CI: 1.3-3.8). A history of smoking is associated with an increased risk for the development of IPF. Although there was no clear exposure-response pattern with the cumulative consumption of cigarettes, there was a trend for time since cessation of smoking, with the highest risk for those who had quit most recently [10] .
Nishikiori et al. [11] studied bronchoalveolar lavage fluid (BALF) and serum levels in IPF, sarcoidosis (group II), and healthy controls (group I). In BALF, they found comparable SP-A levels between the groups; also, significantly lower SP-D levels were found in IPF patients compared with others. However, in IPF, the two proteins reduced in the BALF/serum, and the change in SP-D was more obvious than in SP-A, which indicated greater disease effects for SP-D [11] .
In agreement with these results, Barlo et al. [12] studied several IPF groups and found that serum SP-D was significantly higher in patients compared with the controls. After 1 year, 460 ng/ml appears to be the optimal cut-off serum level to differentiate survivors from nonsurvivors. More over levels more than 460 ng/ml had 13 months median survival versus 67 months in group with levels less than 460 ng/ml. Thus, from these results, they observed that SP-D is a significant predictor of prognosis and a good indicator of lung injury, inflammation, and permeability [12] .
In contrast, Kinder et al. [13] studied the relation between SP-D and SP-A serum levels and mortality in IPF patients. Regression presentation, clinical data, and biomarkers were used for mortality prediction after 1 year. They concluded that in IPF, elevated serum SP-A is a strong independent early mortality marker; moreover, dual elevated serum SP-A and SP-D levels were superior to elevated SP-A alone, but there was no statistically significant relation between mortality and serum SP-D [13] .
Ishii et al. [7] reported that serum SP-A and SP-D levels were higher in most UIP pattern patients. SP-A levels were significantly higher than those in nonspecific interstitial pneumonia patients.Greene et al. [14] studied IPF of different categories, (chronic beryllium disease, systemic sclerosis, sarcoidosis) compared with control volunteers. Serum SP-A and SP-D showed significantly elevated levels in IPF and systemic sclerosis on comparing sarcoidosis, beryllium diseases, and normal controls. They also concluded that both SP-A and SP-D serum levels were good predictors of survival in IPF [14] .
The findings of our study were in agreement with those of many authors; they found that pulmonary function data (FVC% of predicted and FEV 1 % of predicted) were significantly lower in patients compared with controls.
Fernando et al. [15] carried out a study on 19 patients with IPF and they performed repeated pulmonary function tests. They observed a decrease in FVC, total lung capacity, or diffusing capacity of the lungs for carbon monoxide is a medical test that determines how much oxygen travels from the alveoli of the lungs to blood stream (Dl CO ) by 1.5 year in those who had progression of disease during the 3-year follow-up [15] .
Agmy et al.
[16] studied several groups of IPF and healthy individuals, and observed that spirometric data of their IPF patients showed a severe restrictive dysfunction in about 55%, whereas moderate and mild restrictive dysfunctions were observed in about 40 and 5%, respectively.
Conclusion
In IPF patients, statistically significantly elevated serum SP-D was detected. Therefore, SP-D is crucial and increases to different levels in acute and chronic lung diseases. Further studies are needed to determine the prognosis and outcome, and the use for direct treatment efficacy.
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